Business Wire

CA-ASM-GLOBAL

23.5.2024 15:01:28 CEST | Business Wire | Press release

Share
THE ROLLING STONES ADD ADDITIONAL TOUR DATE IN MISSOURI FOR THE STONES TOUR ‘24 HACKNEY DIAMONDS

Today, The Rolling Stones have announced they will be extending the STONES TOUR ’24 HACKNEY DIAMONDS with an additional stop in Ridgedale, Missouri, on July 21 at Thunder Ridge Nature Arena. Tickets are on sale Friday, May 31, 2024, at 10 a.m. local time. For ticketing information, please visit www.rollingstones.com.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240523672007/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

(Graphic: Business Wire)

Mick, Keith and Ronnie kicked off their wildly anticipated tour in Houston, Texas, last month and have brought their legendary show to cities across the United States, including the New Orleans Jazz and Heritage Festival, treating fans to their iconic hits and new music from their critically acclaimed new album HACKNEY DIAMONDS. The STONES TOUR ‘24 HACKNEY DIAMONDS will make stops in 12 more cities across the U.S. and Canada with stops in East Rutherford, Foxboro, Orlando, Atlanta, Philadelphia, Cleveland, Denver, Chicago, Vancouver, Los Angeles and Santa Clara with a final stop in Ridgedale. Full tour routing is below.

Hackney Diamonds is their first studio set of new material since 2005’s A Bigger Bang. Since then, the Stones have continued to smash box office records on a series of global sell-out tours and released 2016’s GRAMMY® Award winning Blue & Lonesome, which featured their brilliant versions of many of the blues tracks that helped shape their sound and topped album charts around the world. In 2022, they thrilled European audiences totaling nearly a quarter of a million on the anniversary Sixty tour. The Rolling Stones have sold over 250 million albums worldwide.

Thunder Ridge Nature Arena — a decade in planning, development and construction with the ambition to create America’s most beautiful outdoor amphitheater — is scheduled to open this May as a one-of-a-kind immersive outdoor “musical postcard from Mother Nature.” Located in Ridgedale, Missouri, just a few miles from Branson, Thunder Ridge Nature Arena is described by its creator and visionary — noted conservationist and Bass Pro Shops founder Johnny Morris as a “gift of the Ozarks to the world.” It is the only venue on Earth completely dedicated to conservation.

AEG Presents’ Concerts West is the promoter of the Stones Tour ’24 Hackney Diamonds. For tickets and information, head to www.rollingstones.com.

THE ROLLING STONES – STONES TOUR ‘24 HACKNEY DIAMONDS
Sponsored by AARP

Thursday, May 23, 2024

MetLife Stadium

East Rutherford, NJ

Sunday, May 26, 2024

MetLife Stadium

East Rutherford, NJ

Thursday, May 30, 2024

Gillette Stadium

Foxboro, MA

Monday, June 3, 2024

Camping World Stadium

Orlando, FL

Friday, June 7, 2024

Mercedes-Benz Stadium

Atlanta, GA

Tuesday, June 11, 2024

Lincoln Financial Field

Philadelphia, PA

Saturday, June 15, 2024

Cleveland Browns Stadium

Cleveland, OH

Thursday, June 20, 2024

Empower Field at Mile High

Denver, CO

Thursday, June 27, 2024

Soldier Field

Chicago, IL

Sunday, June 30, 2024

Soldier Field

Chicago, IL                    

Friday, July 5, 2024

BC Place

Vancouver, BC

Wednesday, July 10, 2024

SoFi Stadium

Los Angeles, CA

Saturday, July 13, 2024

SoFi Stadium

Los Angeles, CA

Wednesday, July 17, 2024

Levi’s® Stadium

Santa Clara, CA

Sunday, July 21, 2024

Thunder Ridge Nature Arena

Ridgedale, MO

 www.youtube.com/user/therollingstones
www.instagram.com/therollingstones
www.tiktok.com/@therollingstones
www.facebook.com/therollingstones
www.twitter.com/rollingstones
www.aegpresents.com

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240523672007/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release

Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P

Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release

Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result

Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release

Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said

SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release

In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin

Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release

Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye